Foghorn Therapeutics Appoints CFO Ryan Maynard, Bringing $1B Funding Track Record
Foghorn Therapeutics appointed Ryan Maynard as CFO on February 23, 2026, tapping his 25 years of biopharma financial leadership. Maynard led over $1 billion in financings and strategic deals at Cara Therapeutics, expected to strengthen Foghorn’s capital strategy as its Lilly-partnered dose escalation advances.
1. CFO Appointment and Background
On February 23, 2026, Foghorn Therapeutics named Ryan Maynard as Chief Financial Officer, leveraging his more than 25 years of financial leadership in public and private biopharmaceutical companies.
2. Track Record in Capital Markets
Maynard has overseen over $1 billion in public and private financings, executed strategic transactions including a $37.5 million non-dilutive royalty deal, and guided FDA approval launch planning for TAVALISSE®.
3. Strategic Implications for Foghorn
Maynard’s expertise is expected to enhance disciplined capital allocation, optimize cash runway and support long-term growth as Foghorn advances its clinical and preclinical pipeline.
4. Pipeline Progress and Financial Support
Foghorn’s lead candidate continues dose escalation in partnership with Eli Lilly, while its selective degrader portfolio nears clinical entry, underscoring the need for robust financial oversight.